3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
Rivaroxaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prevention of Venous Thromboembolism
×
Rivaroxaban
×
Clear all
NCT03055026
2022-03-11
PRO-LAPSII
Fadoi Foundation, Italy
Phase 3
Completed
582 enrolled